Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

reparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor StatementStatements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the plans, timing and trial design of the planned ANA598 Phase IIb and ANA773 Phase IIa studies; (ii) the belief that the design of the planned ANA598 Phase IIb study will support a broad range of potential treatment opportunities in future Phase III studies; (iii) assessments of the potency and safety profile of ANA598 based on the 12 week results; and (iv) references to exploring potential strategic transactions.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies, including the ANA598 data presented at AASLD and available on Anadys' website, may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval.  Also, Anadys cannot provide any assurances that activities related to its exploration of potential strategic transactions will result in a transaction of a particular structure, on favorable terms, or at all. In addition, Anadys' results may be affected by competition from other biotechnology and pharma
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 The new ... safe as the previous version used prior to 2010, ... Kaiser Permanente study published today in Vaccine. ... use beginning in 2010 after a series of trials. ... broader range of pneumococcal types than the previously used ...
(Date:5/22/2013)... 22, 2013  Milliman, Inc., a premier global consulting ... 2013 Milliman Medical Index (MMI), which measures the healthcare ... healthcare benefits through an employer-sponsored preferred provider organization (PPO) ... in 2013 is $22,030. "For the ... on a percentage basis was the lowest in the ...
(Date:5/22/2013)... CLEVELAND , May 22, 2013 /PRNewswire/ ... Software,s enterprise content management (ECM) ... Meditech,s Hospital Information System .  These organizations ... IT system and will use OnBase to ... corporate initiatives.   (Logo:  ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3
... Sept. 19 Women with postmenopausal,osteoporosis receiving ... in bone mineral density (BMD) to those,receiving ... new,study presented at the 29th Annual Meeting ... Research. The study, called MOTION (Monthly ...
... Corporation,today released detailed data from completed studies ... antibiotic drug candidate, oritavancin, to that of,other ... resistant strains of,gram- positive bacteria. Results are ... Conference on Antimicrobial Agents and Chemotherapy,(ICAAC) taking ...
Cached Medicine Technology:New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis 2New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis 3New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis 4Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 3Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 4Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 5
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 ... now have access to Adapt Courseware’s new ... in an adaptive framework that responds based on ... Courseware , the provider of comprehensive adaptive online ... is continuing to develop introductory level general education ...
(Date:5/22/2013)... 22, 2013 Ethos Spa Skin and ... fit for the busy lifestyle of the modern man and ... appropriate for the occasion, whether it is for an anniversary ... or any other occasion. , Clients should know that they ... card designs on the Ethos Spa’s website, ranging from ...
(Date:5/22/2013)... Toppik and Bosley hair fibers, two hair loss concealer products ... hair. Hair loss treatments can be a lengthy process. In ... waiting period, one can use these hair loss concealers. They ... surgery in general. , Bosley and Toppik Hair Thickening ... eliminate the appearance of balding and thinning hair. It is ...
(Date:5/22/2013)... 2013 The health care crisis in the ... up to twenty-seven percent of all adults are without health ... citizens in the U.S. are related to medical bills. ... meaning that many patients cannot afford to take their prescriptions ... at all. That's why MedicationDiscountCard.com is offering savings of ...
(Date:5/22/2013)... 22, 2013 Officials with Alliance Commercial ... cicada services are now in full effect due to ... cicada cycle emerges. , “The cicada emerges in ... they will emerge, so we’re now offering services to ... protected during the invasion,” said R. Brett Madden, Esq., ...
Breaking Medicine News(10 mins):Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 2Health News:Adapt Courseware Releases Introduction to Sociology for Colleges and Universities Nationwide 3Health News:Ethos Spa Skin And Laser Center Has Launched Their Customizable Gift Certificates 2Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2Health News:Alliance Commercial Pest Control, Inc. Now Offering Cicada Protection Services 2
... by Ohio State University that chose to study the mind-set of ... no compunctions opening up to others about their HIV status. ... study Julianne Serovich says, “I was very surprised at how little ... who deliberate very carefully on whether or not to tell people. ...
... was found that via online auction home-made ecstasy kit ... that// eBay sold various chemicals. The purchase was done ... done varying from laboratory and security equipment to precursor ... from July 2005 to April 2006. Local Investigators were ...
... results about a three-stage brain surgery, performed on 25 ... intractable seizures. ,Sadly, none of the treatments ... a special diet —could quell the electrical storms in ... disease called tuberous sclerosis, the seizures began when he ...
... Health conscious people here lawyers in California have sued PepsiCo ... benzene//., ,The drink in question is Pepsi Twist drink, ... three' soft drinks firms has been drawn into a legal ... the lawsuit, "Pepsi Twist has been falsely promoted as a ...
... research from Kansas State University have revealed that males tend ... whereas women on average often// use more protective strategies such ... spent on drinking, counting the number of drinks, and eating ... from the point of view of a whole class of ...
... which is believed to play a key role in the ... added that the revelation could be of immensely helpful for ... of an enzyme called telomerase is believed to contribute to ... human tumors. A lack of detailed information regarding its structure ...
Cached Medicine News:Health News:Intractable Seizures Can Be Handled By A Three-Stage Brain Operation, Neurosurgeon 2Health News:Intractable Seizures Can Be Handled By A Three-Stage Brain Operation, Neurosurgeon 3
... The Wampole EBV ELISA test ... of assays for the determination ... tests for Viral Capsid Antigen ... Nuclear Antigen (EBNA). Most Wampole ...
HSV 1 & HSV 2 DFA Test....
Cytomegalovirus IgM ELISA....
Blunt tipped forceps with long thin tips (3 mm) angled at approximately 120. For grasping of subretinal membranes. Color Coding: Gold....
Medicine Products: